SUMATRIPTAN SUCCINATE | N020132 | GLAXOSMITHKLINE
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Hyman, Phelps & McNamara, P.C. FDA-2023-P-4784 · 7 docket documents Hyman, Phelps & McNamara, P.C., on behalf of a client, submitted a suitability petition under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the FDA declare sumatriptan oral solution in 25 mg/5 mL, 50 mg/5 mL, 75 mg/5 mL, and 100 mg/5 mL strengths suitable for submis | Suitability | 2023-10-30 | Denied | Hyman, Phelps & McNamara, P.C. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$72.38
per ea
Lowest NADAC/Unit
$72.38
per ea
Brand NDCs
1
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00173073701IMITREX 100 MG TABLET | $72.38 | EA | Brand | $0.4341 | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.